Eli Lilly Record at $1 Trillion as GLP-1 Boom Lifts LLY
Can Eli Lilly’s record run keep defying gravity as GLP-1 dominance and billion-dollar dealmaking reshape Big Pharma? Maik Kemper Editor in Chief Lilly’s AI-infused commercial engine is now…
Can Eli Lilly’s record run keep defying gravity as GLP-1 dominance and billion-dollar dealmaking reshape Big Pharma? Maik Kemper Editor in Chief Lilly’s AI-infused commercial engine is now…
Can the new Lululemon Board turn a battered stock into a credible comeback story? Maik Kemper Editor in Chief Lululemon looks cheap, but it’s early to call this…
Did one brutal global tech selloff just expose how fragile the AI trade has become for Nasdaq 100 investors? Maik Kemper Editor in Chief We continue to believe…
Can Micron Earnings and $100 billion in contracts outweigh a brutal selloff, or is AI memory enthusiasm already peaking? Maik Kemper Editor in Chief We believe our multi-year…
Did Micron’s $50 billion outlook just revive the AI trade, or is the Fed about to spoil the rebound? Maik Kemper Editor in Chief Even during COVID Apple…
Can the SpaceX IPO defend its sky-high valuation after a brutal ESG downgrade and a $25 billion debt move? Maik Kemper Editor in Chief We expected SpaceX to…
Is the Netflix Rebound the start of a real trend change, or just a sharp bounce from a deeply oversold level? Maik Kemper Editor in Chief Netflix’s current…
Can Qualcomm’s AI roadmap justify investor patience before its data center chips generate meaningful revenue? Maik Kemper Editor in Chief NVIDIA absolutely dominates the market and whatever’s left,…
Is the Palantir Rebound just an oversold bounce, or the first sign that institutional money is rotating back into AI software? Maik Kemper Editor in Chief Palantir is…
Can Vertiv Data Center turn its 800VDC and liquid-cooling lead into lasting gains after a sharp 6.7% stock drop? Maik Kemper Editor in Chief And from a timing…